Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GammaDelta Therapeutics
I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.
European biotechs are likely to be the big winner as transatlantic VC Abingworth closes its latest fund, Abingworth Ventures VII (ABV VII), at $315m, exceeding its $300m target.
Appointments: Sanofi, Celgene, TeGenix, Allogene, Aimmune, TikoMed and Ionis Announce Changes At The Top
This week's appointments include a new CFO at Sanofi, a new general counsel at Celgene plus new hires at TiGenix, Allogene Therapeutics, Aimmune Therapeutics, TikoMed and Ionis Pharmaceuticals, among others.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Adaptate Biotherapeutics
- Lymphact – Lymphocyte Activation Technologies, S.A.